Therapeutic Solutions International Files to Initiate Phase III Clinical Trial for Acute Respiratory Distress Syndrome (ARDS) Leveraging Positive COVID-19 Data with JadiCell Stem Cell Therapy
Regenerative Medicine Company Leverages Recent Patent Victory and Positive Results to Accelerate Late-Stage Clinical Pulmonary Candidate
ARDS is a condition in which lung injury causes fluid to leak into the spaces between the capillaries and the alveoli. Pressure on the alveoli increases, and eventually fluid accumulates. Fluid in the lungs causes the alveoli to collapse, leading to a series of cascading problems, each further decreasing the lungs’ capacity to move oxygen into the blood, and directly impacting the body’s tissues and organs. ARDS afflicts approximately 190,000 Americans a year1 and is expected to reach a
The decision of the Company to accelerate development of the ARDS programs came in part from a published decision from the
“The Company has stayed a steady course in accomplishing its milestones of in-licensing an advanced cell therapeutic product, filing additional patents surrounding it, demonstrating in animal models and various clinical situations benefits of the product, and now taking the next step in product development by filing for entry into the ARDS patient population, which presents a significantly greater market than COVID-19 induced ARDS,” said Dr.
“We are happy to report the decision of our medical advisors to support entry of our adult stem cell based product into the greater patient population of ARDS,” said
About
1 Acute Respiratory Distress Syndrome (ARDS) > Fact Sheets > Yale Medicine
2 Global Acute Respiratory Distress Syndrome Market
3 ptab-filings/IPR2021-01535/42
4 https://pubmed.ncbi.nlm.nih.gov/33400390/
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005538/en/
ir@tsoimail.com
Source: